Fibrates in Pediatric Cholestasis

• Status: Completed
• Trial end date: 2018-06-20
• Target enrollment: 0
• Participant gender: All

Summary

A study conducted to assess the effect of fibrates on pruritus and biochemical picture in pediatric patients with cholestatic liver diseases.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoda A. Atta
• Treatments: Clofibric Acid; Fenofibrate; Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Patient with chronic cholestatic liver disease defined as any condition in which substances normally excreted into bile are retained for more than 6 months.

Exclusion Criteria:

• Patients with anatomical or mechanical obstructive causes for cholestasis.

• Cholestatic patients who were suffering from another liver disease.

• Cholestatic patients who were receiving drugs affecting lipid profile.

• Patients receiving drugs that interact with Fenofibrate (FF) e.g statins and warfarin

• Patients with non obstructive gall bladder stones were excluded from T gp.